ENSOCELL LTD
Company number 14714531 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
£12,999,654
Balance sheet as at 2026-03-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2023-03-08
- Employees
- 15 (2026 accounts · was 7 in 2025)
- Registered office
- The Eddeva Building, B920, Babraham Research Campus, Cambridge, England, CB22 3AT
- Postcode
- CB22 3AT
- Capital
- 478 GBP
- Accounts category
- Total Exemption Full
Accounts
- Last made up to
- 2026-03-31
- Next due by
- 2027-12-31
- Financial year end
- 31 March
Confirmation statement
- Last statement dated
- 2026-03-07
- Next due by
- 2027-03-21
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 8 current · 4 resigned
Licensed visa sponsor
Licensed by the Home Office to sponsor worker visas: Skilled Worker (Worker (A rating)).
Matched by registered name to the register of licensed sponsors (Home Office, updated daily) — check the register itself before relying on it. Contains public sector information licensed under the Open Government Licence v3.0.
Data protection registration
Registered with the ICO as a data protection fee payer — ZB701375 (Tier 1), registered since 2024.
Information Commissioner's Office register of fee payers, licensed under the Open Government Licence.
Contact details
- Website
- ensocell.com
Ensocell uses spatial-omics and AI/ML to pinpoint disease drivers and predict treatment responses, developing precision biologics for fibrotic diseases.
Previous company names
| Name | Date changed |
|---|---|
| ENSOTX LTD | 2023-07-06 |
Among its peers
Top 10%
by shareholders' funds, of 238 similar companies in CB
Among the biggest employers among its local peers (15 staff).
Trading since 2023.
No.12 of the largest research and experimental development on biotechnology companies in Cambridge →
Competitors Cambridge
This company ranks 12 among research and experimental development on biotechnology in Cambridge.